DSpace Repository

Personalised Medicine Implementation in Lowand Middle-Income Countries

Show simple item record

dc.contributor.author GUSILA, Ilenuta
dc.contributor.author TOPA, Alexandra
dc.contributor.author ZARBAILOV, Natalia
dc.contributor.author LUNGU, Natalia
dc.contributor.author CUROCICHIN, Ghenadie
dc.date.accessioned 2023-11-16T08:23:15Z
dc.date.available 2023-11-16T08:23:15Z
dc.date.issued 2023
dc.identifier.citation GUSILA, Ilenuta, TOPA, Alexandra, ZARBAILOV, Natalia et al. Personalised Medicine Implementation in Lowand Middle-Income Countries. In: 6th International Conference on Nanotechnologies and Biomedical Engineering: proc. of ICNBME-2023, 20–23, 2023, Chisinau, vol. 2: Biomedical Engineering and New Technologies for Diagnosis, Treatment, and Rehabilitation, 2023, p. 411-420. ISBN 978-3-031-42781-7. e-ISBN 978-3-031-42782-4. en_US
dc.identifier.isbn 978-3-031-42781-7
dc.identifier.isbn 978-3-031-42782-4
dc.identifier.uri https://doi.org/10.1007/978-3-031-42782-4_44
dc.identifier.uri http://repository.utm.md/handle/5014/24854
dc.description Acces full text - https://doi.org/10.1007/978-3-031-42782-4_44 en_US
dc.description.abstract The potential of Personalised Medicine makes it attractive to health systems, and personalised approaches are being applied in practice in highly developed countries. However, the implementation of personalised medicine in low- and middle-income countries (LMICs) faces a number of barriers. In this group of countries, where resources allocated for health are limited, innovation is often not a priority. Methods: database search was used to identify publication that describes barriers and prerequisites for the implementation of personalised medicine in LMICs. Results. Insufficient regulation, lack of necessary infrastructure, high costs, lack of training of healthcare providers, low awareness of policy makers and population about benefits are barriers to the implementation of personalised medicine. Strengthening research in the field of personalised medicine, aligned with international standards, on a continuous basis, generating evidence on the long-term benefits of personalised medicine is a prerequisite for the implementation of personalised medicine in LMICs. The collaboration between researchers, information exchange and knowledge transfer between different actors of the health system is an essential element to overcome barriers to the implementation of personalised medicine. Ensuring access to personalised medicine services by identifying solutions to reduce health inequalities is a priority for implementing personalised approaches in health systems in LMICS. Conclusion. Prioritization of personalised medicine at the national level will ensure the strengthening of research, financing and the creation of infrastructure necessary for implementation. Consolidated efforts of all actors involved: health system actors, decision makers, citizens are needed to develop and implement personalised medicine in low- and middle-income countries. en_US
dc.language.iso en en_US
dc.publisher Springer Nature Switzerland en_US
dc.rights Attribution-NonCommercial-NoDerivs 3.0 United States *
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/us/ *
dc.subject personalised medicine en_US
dc.subject middle-income countries en_US
dc.subject health systems en_US
dc.title Personalised Medicine Implementation in Lowand Middle-Income Countries en_US
dc.type Article en_US


Files in this item

The following license files are associated with this item:

This item appears in the following Collection(s)

  • 2023
    6th International Conference on Nanotechnologies and Biomedical Engineering, September 20–23, 2023, Chisinau, Moldova

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States

Search DSpace


Advanced Search

Browse

My Account